domstat.net

Website loading time

during the test: 0.77 s

cable connection (average): 0.8 s

DSL connection (average): 0.82 s

modem (average): 2.24 s

HTTP headers

HTTP/1.1 200 OK

Content-Type: text/html

Last-Modified: Thu, 20 Oct 2011 14:17:22 GMT

Accept-Ranges: bytes

ETag: "05a6fb328fcc1:0"

Server: Microsoft-IIS/7.5

X-Powered-By: ASP.NET

Date: Fri, 21 Oct 2011 04:54:19 GMT

Connection: close

Content-Length: 10503

Information about DNS servers

Received from the first DNS server

Request to the server "neodynamics.se"
You used the following DNS server:
DNS Name: dns10.activeisp.com
DNS Server Address: 213.188.128.40#53
DNS server aliases:

HEADER opcode: REQUEST, status: NOERROR, id: 56491
flag: qr aa rd REQUEST: 1, ANSWER: 8, AUTHORITY: 0, ADDITIONAL: 3

REQUEST SECTION:
neodynamics.se. IN ANY

ANSWER SECTION:
neodynamics.se. 3600 IN SOA dns10.activeisp.com. registry.activeisp.com. 2011083101 86400 7200 3600000 172800
neodynamics.se. 86400 IN NS dns11.activeisp.com.
neodynamics.se. 86400 IN NS dns10.activeisp.com.
neodynamics.se. 86400 IN NS dns12.activeisp.com.
neodynamics.se. 86400 IN MX 10 mtx3.mbn1.net.
neodynamics.se. 86400 IN MX 10 mtx2.mbn1.net.
neodynamics.se. 86400 IN MX 10 mtx1.mbn1.net.
neodynamics.se. 86400 IN A 213.188.134.229

SECTION NOTES:
dns10.activeisp.com. 3600 IN A 213.188.128.40
dns11.activeisp.com. 3600 IN A 213.188.129.40
dns12.activeisp.com. 600 IN A 194.19.37.41

Received 285 bytes from address 213.188.128.40#53 in 103 ms

Received from the second DNS server

Request to the server "neodynamics.se"
You used the following DNS server:
DNS Name: dns11.activeisp.com
DNS Server Address: 213.188.129.40#53
DNS server aliases:

HEADER opcode: REQUEST, status: NOERROR, id: 62791
flag: qr aa rd REQUEST: 1, ANSWER: 8, AUTHORITY: 0, ADDITIONAL: 3

REQUEST SECTION:
neodynamics.se. IN ANY

ANSWER SECTION:
neodynamics.se. 3600 IN SOA dns10.activeisp.com. registry.activeisp.com. 2011083101 86400 7200 3600000 172800
neodynamics.se. 86400 IN A 213.188.134.229
neodynamics.se. 86400 IN MX 10 mtx1.mbn1.net.
neodynamics.se. 86400 IN MX 10 mtx3.mbn1.net.
neodynamics.se. 86400 IN MX 10 mtx2.mbn1.net.
neodynamics.se. 86400 IN NS dns12.activeisp.com.
neodynamics.se. 86400 IN NS dns11.activeisp.com.
neodynamics.se. 86400 IN NS dns10.activeisp.com.

SECTION NOTES:
dns10.activeisp.com. 3600 IN A 213.188.128.40
dns11.activeisp.com. 3600 IN A 213.188.129.40
dns12.activeisp.com. 600 IN A 194.19.37.41

Received 285 bytes from address 213.188.129.40#53 in 108 ms

Subdomains (the first 50)

Typos (misspells)

Location

IP: 213.188.134.229

continent: EU, country: Norway (NOR), city:

Website value

rank in the traffic statistics:

There is not enough data to estimate website value.

Basic information

website build using CSS

code weight: 10.26 KB

text per all code ratio: 29 %

title: NeoDynamics AB | Medical Equipment for Cancer Management

description:

keywords:

encoding: us-ascii

language: en

Website code analysis

one word phrases repeated minimum three times

two word phrases repeated minimum three times

three word phrases repeated minimum three times

B tags

Diagnostics - Fine needle Diagnostics - Fourier/AS Treatment - PRFA var vbImgPath="index-files/" Home About us Projects Publications Team Partnership Press News Contact Safe diagnosis and minimally invasive treatment of cancer

Over the past 25 years, breast cancer incidence rates have risen globally, with the highest rates in Westernized countries. Reasons for this trend include change in reproductive patterns, increased screening, dietary changes, and decreased activity. NeoDynamics has already developed prototypes of both the therapeutic (PRFA) as well as diagnostic device (Fourier/AS). Further development in order to have marketable devices is being done in close cooperation with Key Opinion Leaders in respective market, both for developing the optimal launchable tools and paving the way for acceptance for both these novel and highly innovative approaches in the market place. PRFA will initially be positioned as an option to surgery in the treatment of elderly and high risk patients, as well as adjuvant treatment for other breast cancer patients. Furthermore, PRFA is an ideal treatment option for patients with Fibroadenoma, which is the most common cause of breast mass in women younger than 35 years. Fourier/AS will be positioned as a high end ultrasound guided core biopsy device for the diagnosis of breast cancer Newsfeed September 12, 2011 We are proud to announce that Karl Swartling and Mats Carlson have joined the board of directors. Their experience and knowledge will be of significant value for the company. More information on their respective backgrounds can be found here

May 1, 2011 It is our pleasure to welcome Peter Sellei M.D. as new CEO to NeoDynamics AB. His vast experience and professionel background in developing life science companies will enable NeoDynamics to reach its goal of providing healthcare with innovative medtech products. Peter Sellei was previously active at Investor AB and board member of several companies in the life science sector. April 4, 2011 NeoDynamics' PRFA cancer treatment technology was featured in the Swedish science television programme "Vetenskapens Värld". The feature, about 4 minutes into the programme, is available here

February 11, 2011 A newspaper article about our projects has been published in Affärstidningen Näringsliv. Its online version can be found here

news archive...

U tags

I tags

Diagnostics - Fine needle Diagnostics - Fourier/AS Treatment - PRFA var vbImgPath="index-files/" Home About us Projects Publications Team Partnership Press News Contact Safe diagnosis and minimally invasive treatment of cancer Over the past 25 years, breast cancer incidence rates have risen globally, with the highest rates in Westernized countries. Reasons for this trend include change in reproductive patterns, increased screening, dietary changes, and decreased activity. NeoDynamics has already developed prototypes of both the therapeutic (PRFA) as well as diagnostic device (Fourier/AS). Further development in order to have marketable devices is being done in close cooperation with Key Opinion Leaders in respective market, both for developing the optimal launchable tools and paving the way for acceptance for both these novel and highly innovative approaches in the market place. PRFA will initially be positioned as an option to surgery in the treatment of elderly and high risk patients, as well as adjuvant treatment for other breast cancer patients. Furthermore, PRFA is an ideal treatment option for patients with Fibroadenoma, which is the most common cause of breast mass in women younger than 35 years. Fourier/AS will be positioned as a high end ultrasound guided core biopsy device for the diagnosis of breast cancer Newsfeed September 12, 2011 We are proud to announce that Karl Swartling and Mats Carlson have joined the board of directors. Their experience and knowledge will be of significant value for the company. More information on their respective backgrounds can be found here. May 1, 2011 It is our pleasure to welcome Peter Sellei M.D. as new CEO to NeoDynamics AB. His vast experience and professionel background in developing life science companies will enable NeoDynamics to reach its goal of providing healthcare with innovative medtech products. Peter Sellei was previously active at Investor AB and board member of several companies in the life science sector. April 4, 2011 NeoDynamics' PRFA cancer treatment technology was featured in the Swedish science television programme "Vetenskapens Värld". The feature, about 4 minutes into the programme, is available here. February 11, 2011 A newspaper article about our projects has been published in Affärstidningen Näringsliv

images

headers

H1

H2

H3

H4

H5

H6

internal links

external links